ZA200803278B - Parasiticide composition - Google Patents
Parasiticide composition Download PDFInfo
- Publication number
- ZA200803278B ZA200803278B ZA200803278A ZA200803278A ZA200803278B ZA 200803278 B ZA200803278 B ZA 200803278B ZA 200803278 A ZA200803278 A ZA 200803278A ZA 200803278 A ZA200803278 A ZA 200803278A ZA 200803278 B ZA200803278 B ZA 200803278B
- Authority
- ZA
- South Africa
- Prior art keywords
- composition according
- fatty acid
- ethoxylates
- group
- acid esters
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 66
- 230000000590 parasiticidal effect Effects 0.000 title claims description 4
- 239000002297 parasiticide Substances 0.000 title claims description 4
- -1 glycol ethers Chemical class 0.000 claims description 35
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 25
- 239000000194 fatty acid Substances 0.000 claims description 25
- 229930195729 fatty acid Natural products 0.000 claims description 25
- QNSIFYWAPWSAIJ-UHFFFAOYSA-N naftalofos Chemical compound C1=CC(C(N(OP(=O)(OCC)OCC)C2=O)=O)=C3C2=CC=CC3=C1 QNSIFYWAPWSAIJ-UHFFFAOYSA-N 0.000 claims description 23
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 22
- 239000003381 stabilizer Substances 0.000 claims description 19
- 239000004094 surface-active agent Substances 0.000 claims description 12
- 150000001298 alcohols Chemical class 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 9
- 239000003960 organic solvent Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 8
- 150000005215 alkyl ethers Chemical class 0.000 claims description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 7
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 7
- 150000004040 pyrrolidinones Chemical class 0.000 claims description 7
- NFACJZMKEDPNKN-UHFFFAOYSA-N trichlorfon Chemical compound COP(=O)(OC)C(O)C(Cl)(Cl)Cl NFACJZMKEDPNKN-UHFFFAOYSA-N 0.000 claims description 7
- BOFHKBLZOYVHSI-UHFFFAOYSA-N Crufomate Chemical compound CNP(=O)(OC)OC1=CC=C(C(C)(C)C)C=C1Cl BOFHKBLZOYVHSI-UHFFFAOYSA-N 0.000 claims description 6
- BXNANOICGRISHX-UHFFFAOYSA-N coumaphos Chemical compound CC1=C(Cl)C(=O)OC2=CC(OP(=S)(OCC)OCC)=CC=C21 BXNANOICGRISHX-UHFFFAOYSA-N 0.000 claims description 6
- 229960001952 metrifonate Drugs 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 235000006708 antioxidants Nutrition 0.000 claims description 5
- 239000007900 aqueous suspension Substances 0.000 claims description 5
- KULDXINYXFTXMO-UHFFFAOYSA-N bis(2-chloroethyl) (3-chloro-4-methyl-2-oxochromen-7-yl) phosphate Chemical compound C1=C(OP(=O)(OCCCl)OCCCl)C=CC2=C1OC(=O)C(Cl)=C2C KULDXINYXFTXMO-UHFFFAOYSA-N 0.000 claims description 5
- 229950002363 crufomate Drugs 0.000 claims description 5
- 229950002831 haloxon Drugs 0.000 claims description 5
- 244000078703 ectoparasite Species 0.000 claims description 4
- 239000002736 nonionic surfactant Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 claims description 3
- OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 claims description 3
- OAYXUHPQHDHDDZ-UHFFFAOYSA-N 2-(2-butoxyethoxy)ethanol Chemical compound CCCCOCCOCCO OAYXUHPQHDHDDZ-UHFFFAOYSA-N 0.000 claims description 3
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 claims description 3
- NFIHXTUNNGIYRF-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCC NFIHXTUNNGIYRF-UHFFFAOYSA-N 0.000 claims description 3
- UMZCLZPXPCNKML-UHFFFAOYSA-N 2h-imidazo[4,5-d][1,3]thiazole Chemical class C1=NC2=NCSC2=N1 UMZCLZPXPCNKML-UHFFFAOYSA-N 0.000 claims description 3
- QCAHUFWKIQLBNB-UHFFFAOYSA-N 3-(3-methoxypropoxy)propan-1-ol Chemical compound COCCCOCCCO QCAHUFWKIQLBNB-UHFFFAOYSA-N 0.000 claims description 3
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 3
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims description 3
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 3
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 3
- 239000004166 Lanolin Substances 0.000 claims description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 3
- 150000003973 alkyl amines Chemical class 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 239000002280 amphoteric surfactant Substances 0.000 claims description 3
- 125000000129 anionic group Chemical group 0.000 claims description 3
- 239000003945 anionic surfactant Substances 0.000 claims description 3
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 3
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 3
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 3
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- 125000002091 cationic group Chemical group 0.000 claims description 3
- 239000003093 cationic surfactant Substances 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 244000079386 endoparasite Species 0.000 claims description 3
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 3
- 229940093471 ethyl oleate Drugs 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims description 3
- 125000002183 isoquinolinyl group Chemical class C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 3
- 150000002596 lactones Chemical class 0.000 claims description 3
- 229940039717 lanolin Drugs 0.000 claims description 3
- 235000019388 lanolin Nutrition 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 3
- 229930003799 tocopherol Natural products 0.000 claims description 3
- 239000011732 tocopherol Substances 0.000 claims description 3
- 235000019149 tocopherols Nutrition 0.000 claims description 3
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 claims description 3
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 claims 2
- 238000003756 stirring Methods 0.000 description 14
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000009472 formulation Methods 0.000 description 7
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 7
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 7
- 239000007787 solid Substances 0.000 description 5
- 239000003549 soybean oil Substances 0.000 description 5
- 235000012424 soybean oil Nutrition 0.000 description 5
- IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 description 4
- 239000005660 Abamectin Substances 0.000 description 4
- 229950008167 abamectin Drugs 0.000 description 4
- 235000019445 benzyl alcohol Nutrition 0.000 description 4
- 229960004217 benzyl alcohol Drugs 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 206010061217 Infestation Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- IEORSVTYLWZQJQ-UHFFFAOYSA-N 2-(2-nonylphenoxy)ethanol Chemical compound CCCCCCCCCC1=CC=CC=C1OCCO IEORSVTYLWZQJQ-UHFFFAOYSA-N 0.000 description 1
- BWDBEAQIHAEVLV-UHFFFAOYSA-N 6-methylheptan-1-ol Chemical compound CC(C)CCCCCO BWDBEAQIHAEVLV-UHFFFAOYSA-N 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 description 1
- 229960002669 albendazole Drugs 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- XJHABGPPCLHLLV-UHFFFAOYSA-N benzo[de]isoquinoline-1,3-dione Chemical compound C1=CC(C(=O)NC2=O)=C3C2=CC=CC3=C1 XJHABGPPCLHLLV-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229950004222 coumafos Drugs 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- HDDSHPAODJUKPD-UHFFFAOYSA-N fenbendazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1SC1=CC=CC=C1 HDDSHPAODJUKPD-UHFFFAOYSA-N 0.000 description 1
- 229960005473 fenbendazole Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 229950011528 naftalofos Drugs 0.000 description 1
- 229920000847 nonoxynol Polymers 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003986 organophosphate insecticide Substances 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000004563 wettable powder Substances 0.000 description 1
Landscapes
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Hi #:2000/ 03278
This application claims priority from Australian Innovation Patent Application No. 2007100477 filed on 5 June 2007, the contents of which are hereby incorporated by reference.
This invention relates to organophosphate compositions and in particular to such compositions where the organophosphate is presented in the form of a drench for the prevention or control of endo- and ecto-parasites in warm blooded animals.
There are a number of organophosphate insecticides that are known to be useful for the treatment of parasites in warm blooded animals such as domestic and farm animals. - These include naphthalophos, coumaphos, crufomate, metrifonate and haloxon.
Chemically, naphthalophos (also known as naftalofos) is 2-[(diethoxyphosphinyl)oxy]- : ' 1H-benz[de]isoquinoline-1,3(2H)-dione, coumafos is 3-chloro-7- diethoxyphosphinothioyloxy-4-methylcoumarin, crufomate is (RS)-(4-tert-butyl-2- chlorophenyl methyl methylphosphoramidate), metrifonate (also known as trichlorfon) ~ is dimethyl (RS)-2,2,2-trichloro-1-hydroxyethylphosphonate and haloxon is O,0-di-(2- chloroethyl)-O-(3-chloro-4-methylcoumarin-7-yl) phosphate.
Naphthalophos for example, is practically insoluble in water but is water dispersible.
In order to maintain an acceptable stability profile, it is generally formulated and stored as a wettable powder that may be dispersed in water or in a water-based formulation immediately prior to use.
The wettable naphthalophos powder is highly poisonous to the user if it comes in contact with the skin or eyes, or if the powder is inhaled. Mixing of the powder into the desired solution is time consuming and provides potential for incorrect preparation that can further result in incorrect dosing of an animal being treated. Once the naphthalophos is added to water, it begins to degrade giving a short shelf-life for the made-up dispersion. The reduced shelf-life can be costly to the user as surplus formulation not used during the initial treatment may not retain sufficient potency for treatment at a later time.
The present inventors have recognised the disadvantages of powdered organophosphates and accordingly have sought to provide compositions that are stable and in the form of a suspension. The present inventors have achieved stable solvent- based compositions of organophosphates through the finding that certain solvent combinations with organophosphates result in formulations that are stable and are suitable for oral administration to animals.
Accordingly, in a first aspect, the present invention provides a non-aqueous suspension composition consisting essentially of: a parasiticidally effective amount of at least one organophosphate; one or more organic solvents selected from the group consisting of medium chain triglycerides, alcohols, C;.Cis pyrrolidones, alkyl ethers, glycol ethers, fatty acid esters and glycerol fatty acid esters; one or more stabilising agents; and one or more surfactants.
In a second aspect, the invention provides a method of preventing or controlling endo and ectoparasites in a warm blooded animal, the method comprising orally administering to the animal a non-aqueous suspension composition consisting essentially of: a parasiticidally effective amount of at least one organophosphate; one or more organic solvents selected from the group consisting of medium chain triglycerides, alcohols, C;.Cs pyrrolidones, alkyl ethers, glycol ethers, fatty acid esters and glycerol fatty acid esters; one or more stabilising agents; and one or more surfactants.
In a third aspect the invention further provides use of a non-aqueous suspension composition consisting essentially of: a parasiticidally effective amount of at least one organophosphate; one or more organic solvents selected from the group consisting of medium chain triglycerides, alcohols, C;.C;s pyrrolidones, alkyl ethers, glycol ethers, fatty acid esters and glycerol fatty acid esters; one or more stabilising agents; and one or more surfactants, in the preparation of an oral composition for prevention or control of ecto and endoparasites in a warm blooded animal.
The composition of the present invention may be used for combination therapy as it may include one or more other parasiticides such as those selected from the group consisting of: macrocyclic lactones; salicylanilides; benzimidazoles; imidazothiazoles; and isoquinolines.
Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
Throughout this specification the phrase "consisting essentially of" or variations thereof will be understood to be open-ended but to exclude elements or ingredients that would materially affect the properties/characteristics of the invention described and claimed herein.
Throughout this specification the word "non-aqueous" will be understood to imply that water may be present in the suspension composition in de minimis amounts such as amounts usually present in the individual starting ingredients. The composition contains no more than about 10%w/v water, preferably no more than about 5%w/v water based on the total volume of the composition.
Suitable organophosphates include but are not limited to naphthalophos, coumaphos, crufomate, metrifonate and haloxon. The preferred organophosphate is naphthalophos.
Naphthalophos may be included in the composition in a concentration of up to 30 percent w/v, such as in an amount of from 1 to 30 percent w/v. Preferably, the naphthalophos is included in the composition in an amount of from 10 to 30% w/v, more preferably 10 to 15% w/v and most preferably from 12.5 to 13.5% w/v.
The one or more organic solvents included in the composition are selected from the group consisting of medium chain triglycerides, alcohols, C;.Cis pyrrolidones, alkyl ethers, glycol ethers, fatty acid esters and glycerol fatty acid esters.
Suitable medium chain triglycerides are those with carbon chain link in the order of from 6 to 12.
Suitable alcohols include but are not limited to those with two or more carbon atoms, preferably two to eight carbon atoms such as ethanol, isopropanol, isooctanol and benzyl alcohol.
Suitable C; — Cig pyrrolidones include 2-pyrrolidone and N-methylpyrrolidone.
Suitable glycol ethers include but are not limited to dipropylene glycol monomethylether, butyl icinol and butyl di icinol.
Suitable fatty acid esters include but are not limited to isopropyl myristate, ethyl oleate, and isopropyl palmitate. : Suitable glycerol fatty acid esters include but are not limited to propylene glycol dicaprylate/dicaprate and propylene glycol isocetyth-3-acetate
Suitably alkyl ethers include but are not limited to dimethyl isosorbide.
Preferred organic solvents are one or more fatty acid esters and one or more alcohols, such as caprylic/capric triglyceride and benzyl alcohol.
Surprisingly, use of some conventional organic solvents does not prevent the hydrolysis of the organophosphate. Slightly hygroscopic solvents may absorb moisture from the surrounding environment. The absorbed water molecules hydrolyse the organophosphate, degrading the active and significantly shortening the shelf-life of the product.
The total concentration of the solvent in the composition may be in the range of from 55 to 97.5% w/v, preferably from 65 to 85 % w/v, more preferably from75 to 80 % w/v.
Suitable stabilising agents may be selected from the group consisting of antioxidants, antihydrolytic compounds and glycerol fatty acid esters. Preferred antioxidants include butylated hydroxyanisole, butylated hydroxytoluene and tocopherols. These antioxidants are also antihydrolytic agents. Preferred stabilising agents are glycerol fatty acid esters such as oleochemicals and epoxidised oleochemicals. Suitable oleochemicals include sunflower oil, palm oil, soybean oil and olive oil. More preferred stabilising agents are epoxidised oleochemicals, such as epoxidised soybean oil.
The stabilising agents in combination with the solvent serve to stabilise the 5 ‘organophosphate against hydrolysis. The stabilising agents act as a water scavenger, reacting with water molecules that may be present in solution before the water can degrade the active.
The total concentration of stabilising agents in the composition may be in the range of from 0.5 to 10% w/v, preferably from 2 to 10 % w/v, most preferably from 7 to 9 % w/v.
The one or more surfactants included in the composition may be selected from non- ionic, anionic, cationic and amphoteric surfactants. Preferably, the surfactants are one or more non-ionic surfactants selected from the group consisting of Cg-C, alkylphenol ethoxylates, Co-Cj; alkyl ethoxylates, Cs-Cy alkyl amine ethoxylates, castor oil ethoxylates, lanolin alcohol ethoxylates, sorbitan fatty acid ester ethoxylates, sorbitan fatty acid esters and mixtures thereof. More preferred surfactants are Cs-Cio alkylphenol ethoxylates and most preferred are Co alkylphenol ethoxylates such as
Teric N8 (a nonyl phenol ethoxylate with 8 ethoxy groups).
Veterinarily acceptable excipients and adjuvants may be included in the composition such as dyes, flavouring agents, thickening agents, dispersing agents and oils. A person skilled in the art would be well aware of appropriate adjuvants suitable for oral veterinary preparations.
Modes for Carrying Out the Invention
Examplel
Component | Quantity | Supplier | Function
Naphthalophos | 135 g/L
Epoxidised Soybean | 80g/L APS stabiliser
Oil triglyceride
A litre of formulation is prepared at room temperature as follows:
Transfer 750 mL of caprylic/capric triglyceride to the manufacturing vessel. Whilst stirring the solution, slowly add the epoxidised soybean oil (ESBO). Stir under medium speed until an optically isotropic solution is achieved.
Add Teric N8 to the solution. Stir under medium speed until an optically isotropic solution is achieved.
Whilst stirring the solution at a low speed, slowly add the Naphthalophos, mix the solution at medium speed until the solid active is homogenously suspended within the solution.
Homogenise the mixture at high speed for 10 minuted to achieve a uniform mixture.
Allow the solution to settle and make up to 1 litre with caprylic/capric triglyceride.
Example 2
Component | Quantity | Supplier | Function
Oil monostearate triglyceride
A litre of formulation is prepared at room temperature as follows:
Transfer 750 mL of caprylic/capric triglyceride to the manufacturing vessel. Whilst stirring the solution, slowly add the epoxidised soybean oil (ESBO). Stir under medium speed until an optically isotropic solution is achieved.
In a separate container, dissolve the abamectin in benzyl alcohol.
Add the abamectin solution to the solution prepared in Step 1. Mix thoroughly under medium speed.
Add Teric N8 to the solution. Stir under medium speed until an optically isotropic solution is achieved.
Whilst stirring the solution at a low speed, slowly add the Naphthalophos, mix the solution at medium speed until the solid active is homogenously suspended within the solution.
Homogenise the mixture at high speed for 10 minuted to achieve a uniform mixture.
Whilst stirring the solution at a low speed, slowly add the albendazole; mix the solution N at medium speed until the solid active is homogenously suspended within the solution.
Homogenise the mixture at high speed for 10 minuted to achieve a uniform mixture
Allow the solution to settle and make up to 1 litre with caprylic/capric triglyceride.
Example 3 (Component | Quantity Supplier | Function
Oil triglyceride
A litre of formulation is prepared at room temperature as follows:
Transfer 750 mL of caprylic/capric triglyceride to the manufacturing vessel. Whilst stirring the solution, slowly add the epoxidised soybean oil (ESBO). Stir under medium speed until an optically isotropic solution is achieved.
In a separate container, dissolve the abamectin in benzyl alcohol.
Add the abamectin solution to the solution prepared in Step 1. Mix thoroughly under medium speed.
Add Teric N8 to the solution. Stir under medium speed until an optically isotropic solution is achieved.
Whilst stirring the solution at a low speed, slowly add the Naphthalophos, mix the solution at medium speed until the solid active is homogenously suspended within the solution.
Homogenise the mixture at high speed for 10 minuted to achieve a uniform mixture.
Whilst stirring the solution at a low speed, slowly add the fenbendazole; mix the solution at medium speed until the solid active is homogenously suspended within the solution.
Homogenise the mixture at high speed for 10 minuted to achieve a uniform mixture
Allow the solution to settle and make up to 1 litre with caprylic/capric triglyceride.
Example 4
Stability Tests
An experimental batch of the formulation described in Example 1 was prepared and stored under real-time conditions (30°C/60% RH) and accelerated conditions (40°C/75% RH) for a period of 3 months. Samples were assessed for appearance, re- suspendability and assayed for strength via HPLC. Results are shown in the table below.
Ea
Appearance . ) suspension suspension
Naphthalophos
RH .
Naphthalophos
Concentration 133.5 g/L 131.0g/L
Strength (40°C/75% RH)
Whilst compositions made according to the invention will find the greatest : application as a drench for treatment or control of parasitic infestations of sheep, goats and camelids including llamas and alpacas, they are also useful in treating parasitic infestations of other ruminants as well as horses, pigs and dogs.
Claims (27)
1. A non-aqueous suspension composition consisting essentially of: a parasiticidally effective amount of at least one organophosphate; one or more organic solvents selected from the group consisting of medium chain triglycerides, alcohols, C,.Cs pyrrolidones, alkyl ethers, glycol ethers, fatty acid esters and glycerol fatty acid esters; one or more stabilising agents; one or more surfactants; and optionally a parasiticidally effective amount of one or more parasiticides selected from the group consisting of macrocyclic lactones, salicylanilides, benzimidazoles, imidazothiazoles and isoquinolines.
2. A composition according to claim 1 wherein the at least one organophosphate is selected from the group consisting of naphthalophos, coumaphos, crufomate, metrifonate and haloxon.
3. A composition according to claim 1 wherein the at least one organophosphate is naphthalophos.
4. A composition according to claim 3 wherein naphthalophos is included in an amount of 1 to 30 % w/v.
5. A composition according to claim 3 wherein naphthalophos is included in an amount of from 10 to 30% w/v.
6. A composition according to claim 3 wherein naphthalophos is included in an amount of 10 to 15% w/v.
7. A composition according to any one of claims 1 to 6 wherein the one or more organic’ solvents is selected from the group consisting of C¢-Ci; medium chain triglycerides, Ciwo or more alcohols, 2-pyrrolidone, N-methylpyrrolidone, dipropylene glycol monomethylether, butyl icinol, butyl di icinol, isopropyl myristate, ethyl oleate, isopropyl palmitate, propylene glycol dicaprylate/dicaprate, propylene glycol isocetyth- 3-acetate and dimethyl isosorbide.
8. A composition according to claim 7 wherein the total amount of solvent included is from 55 to 97.5% w/v.
9. A composition according to claim 7 wherein the total amount of solvent included is from 65 to 85 % w/v.
10. A composition according to claim 7 wherein the total amount of solvent included is from 75 to 80 % w/v.
11. A composition according to any one of claims 1 to 10 wherein the one or more : stabilising agents is selected from the group consisting of antioxidants, antihydrolytic compounds and glycerol fatty acid esters.
12. A composition according to claim 11 wherein the one or more stabilising agents is selected from butylated hydroxyanisole, butylated hydroxytoluene, tocopherols, oleochemicals and epoxidised oleochemicals.
13. A composition according to claim 11 wherein the total amount of stabilising agent included is from 0.5 to 10% w/v.
14. A composition according to claim 11 wherein the total amount of stabilising agent included is from 2 to 10 % w/v.
15. A composition according to claim 11 wherein the total amount of stabilising agent included is from 7 to 9 % w/v.
16. A composition according to any one of claims 1 to 15 wherein the one or more surfactants is selected from non-ionic, anionic, cationic and amphoteric surfactants.
17. A composition according to claim 16 wherein the one or more surfactants is selected from Cg-Ci alkylphenol ethoxylates, Co-C;7 alkyl ethoxylates, Cg-Cyo alkyl amine ethoxylates, castor oil ethoxylates, lanolin alcohol ethoxylates, sorbitan fatty acid ester ethoxylates and sorbitan fatty acid esters.
18. Use of a non-aqueous suspension composition consisting essentially of: a parasiticidally effective amount of at least one organophosphate; one or more organic solvents selected from the group consisting of medium chain triglycerides, alcohols, C,.C;s pyrrolidones, alkyl ethers, glycol ethers, fatty acid esters and glycerol fatty acid esters; one or more stabilising agents; one or more surfactants; and optionally a parasiticidally effective amount of one or more parasiticides selected from the group consisting of macrocyclic lactones, salicylanilides, benzimidazoles, imidazothiazoles and isoquinolines, in the preparation of an oral composition for prevention or control of ecto and endoparasites in a warm blooded animal.
19. Use according to claim 18 wherein the at least one organophosphate is selected from the group consisting of naphthalophos, coumaphos, crufomate, metrifonate and haloxon.
20. Use according to claim 19 wherein the at least one organophosphate is naphthalophos.
*+9008/ 03278
21. Use according to any one of claims 18 to 20 wherein the one or more organic solvents is selected from the group consisting of C4-Ci, medium chain triglycerides, Cwo or more alcohols, 2-pyrrolidone, N-methylpyrrolidone, dipropylene glycol monomethylether, butyl icinol, butyl di icinol, isopropyl myristate, ethyl oleate, isopropyl palmitate, propylene glycol dicaprylate/dicaprate, propylene glycol isocetyth- 3-acetate and dimethyl isosorbide.
22. Use according to any one of claims 18 to 21 wherein the one or more stabilising agents is selected from the group consisting of antioxidants, antihydrolytic compounds and glycerol fatty acid esters.
23. Use according to claim 22 wherein the one or more stabilising agents is selected from butylated hydroxyanisole, butylated hydroxytoluene, tocopherols, oleochemicals and epoxidised oleochemicals.
24. Use according to any one of claims 18 to 23 wherein the one or more surfactants is selected from non-ionic, anionic, cationic and amphoteric surfactants.
25. Use according to claim 24 wherein the one or more surfactants is selected from Cs- Co alkylphenol ethoxylates, Co-C,7 alkyl ethoxylates, Cg-Cyo alkyl amine ethoxylates, castor oil ethoxylates, lanolin alcohol ethoxylates, sorbitan fatty acid ester ethoxylates and sorbitan fatty acid esters.
26. Composition according to claim 1, substantially as hereinbefore described or exemplified.
27 Use according to claim 18, substantially as hereinbefore described or exemplified. DATED THIS 14™ DAY OF APRIL 2008 SPOOR & FISHER APPLICANTS PATENT ATTORNEYS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2007100477A AU2007100477A4 (en) | 2007-06-05 | 2007-06-05 | Parasiticide Composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200803278B true ZA200803278B (en) | 2009-12-30 |
Family
ID=38283853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200803278A ZA200803278B (en) | 2007-06-05 | 2008-04-14 | Parasiticide composition |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2007100477A4 (en) |
| NZ (1) | NZ566169A (en) |
| ZA (1) | ZA200803278B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010101089B4 (en) * | 2010-10-06 | 2013-03-07 | Jurox Pty Limited | Parasiticidal Composition |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1600840A (en) * | 1978-05-30 | 1981-10-21 | Wellcome Found | Diphenylether derivatives useful as flukicidal agents |
| DE19613974A1 (en) * | 1996-04-09 | 1997-10-16 | Bayer Ag | New insecticidal suspension concentrates |
| IT1290845B1 (en) * | 1996-12-12 | 1998-12-14 | Isagro Spa | COMPOSITIONS FOR THE SYSTEMIC CONTROL OF PARASITES OF HOT BLOOD ANIMALS |
| JP2004508283A (en) * | 2000-02-18 | 2004-03-18 | ヨマー、ファルマカ、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツング | Organophosphorus compounds and uses thereof |
| DE10008522A1 (en) * | 2000-02-24 | 2001-09-06 | Hassan Jomaa | Use of 2-phenylenediamine derivatives for the treatment of infections |
| AR045142A1 (en) * | 2003-07-30 | 2005-10-19 | Novartis Ag | BUEN SABOR DUCTILE MASTICABLE VETERINARY COMPOSITION |
-
2007
- 2007-06-05 AU AU2007100477A patent/AU2007100477A4/en not_active Expired
-
2008
- 2008-02-25 NZ NZ56616908A patent/NZ566169A/en not_active IP Right Cessation
- 2008-04-14 ZA ZA200803278A patent/ZA200803278B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ566169A (en) | 2008-07-31 |
| AU2007100477B4 (en) | 2007-07-05 |
| AU2007100477A4 (en) | 2007-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2908094T3 (en) | Localized topical formulation of isoxazoline | |
| CA2476520C (en) | Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound | |
| RU2602189C2 (en) | Topical localized isoxazoline formulation comprising glycofurol | |
| CA2630458C (en) | Benzimidazole non-aqueous compositions | |
| NZ248486A (en) | Stable anthelmintic formulation containing closantel and one or more avermectins or milbemycins in a glycol based solvent | |
| WO2007075827A2 (en) | Homogeneous paste formulations | |
| AU2008282388A1 (en) | Endoparasiticidal topical compositions | |
| KR20120079706A (en) | An insecticidal composition for disinfecting stable and poultry farm | |
| KR20220004158A (en) | Injectable pharmaceutical compositions and uses thereof | |
| JPH05246893A (en) | Long-acting antiparasitic injectable formulation containing hydrogenated castor oil | |
| AU2007100477A4 (en) | Parasiticide Composition | |
| CA2673193C (en) | Homogeneous paste and gel formulations | |
| GB2386067A (en) | Long-acting parasiticidal composition with improved bioavailability comprising an avermectin or milbemycin, plus a salicylanilide & a polymeric species | |
| AU2010101089B4 (en) | Parasiticidal Composition | |
| NZ565548A (en) | Stable anthelmintic veterinary formulations containing naphthalophos | |
| AU2013201479B2 (en) | Long Acting Compositions |